Trinity Biotech Plc Partners with Nalu Medical to Transform Pain Management Solutions
- Trinity Capital commits up to $50 million to Nalu Medical, focusing on neurostimulation for chronic pain management.
- The partnership aims to enhance Nalu's next-generation Therapy Disc and develop extensive real-world data for pain relief.
- Trinity Capital's investment underscores its commitment to advancing medical technology and supporting growth in the life sciences sector.
Trinity Capital Partners with Nalu Medical to Revolutionize Pain Management
On September 16, 2025, Trinity Capital Inc., a key player in alternative asset management based in Phoenix, announces a substantial commitment of up to $50 million in growth funding to Nalu Medical, Inc. This partnership targets the burgeoning field of neurostimulation for chronic neuropathic pain, an area that has seen increasing demand for innovative solutions. Nalu Medical specializes in advanced neurostimulation technologies, particularly their recently FDA-cleared Neurostimulation System, which includes a proprietary implantable pulse generator (IPG). This device is notable for being minimally invasive, battery-free, and controllable via a smartphone, making it a game-changer in pain management.
Rob Lake, Senior Managing Director of Life Sciences at Trinity Capital, expresses pride in the collaboration, emphasizing Nalu's leadership in peripheral nerve stimulation (PNS) and its transformative potential in pain management. The funding is set to bolster Nalu's commercial expansion, particularly for their next-generation Therapy Disc, which is designed to enhance the patient experience and efficacy of treatment. Furthermore, the partnership will facilitate the development of the largest long-term real-world data set for a permanent PNS device, which has already shown promising results in providing long-term pain relief across a diverse patient demographic.
This strategic investment aligns with Trinity Capital's overarching goal of supporting growth-oriented companies in the life sciences sector. By leveraging its expertise in providing tailored debt solutions, Trinity aims to ensure consistent returns for its investors while also fostering innovation in healthcare. The partnership with Nalu Medical not only demonstrates Trinity's commitment to advancing medical technology but also highlights the increasing importance of neurostimulation solutions in addressing chronic pain, a condition affecting millions worldwide.
In addition to its collaboration with Nalu Medical, Trinity Capital has also announced a cash dividend of $0.51 per share for the quarter ending September 30, 2025. This marks the company's 23rd consecutive quarter of stable or increased dividends, reflecting its commitment to shareholder returns. The company has deployed over $4.7 billion across more than 420 investments since its inception in 2008, focusing on tailored debt solutions across five key verticals, including Life Sciences.
Furthermore, Trinity Capital recently committed $100 million in growth capital to Angel Studios, a media company dedicated to values-based storytelling. This investment highlights Trinity's diverse portfolio and commitment to supporting companies that strive to make a positive impact, whether in healthcare or entertainment.
